EP2 receptor signaling supresses TLR3/TLR4 ...

4 downloads 0 Views 999KB Size Report
(LGFG-IGA), Albert-Ludwigs-Universität. Freiburg. Iba1. NeuN. Merge. C o n tro .... University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
EP2 receptor signaling supresses TLR3/TLR4-mediated inflammation in microglia and organotypic hippocampal slice cultures via MAPKs Nizar M. Yousif, Antonio Carlos Pinheiro de Oliveira, Simone Brioschi, Michael Huell, Knut Biber and Bernd L. Fiebich Laboratory of Translational Psychiatry, Department of Psychiatry and Psychotherapy, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany

Introduction Brain inflammation is a critical factor involved in neurodegeneration. In this regard, increased levels of prostaglandin E2 have been found in patients and animal models of AD, PD and ALS, supporting the phenomena that inflammation via the PGE2 pathway is playing a role in these neuropathologies. However, clinical trials with nonsteroidal anti- inflammatory drugs (NSAIDS) that act at the COX-1 and COX-2 level or COX-2 selective inhibitors have failed to hold promises as potential therapy for CNS diseases. In the search for new alternatives, the PGE2 EP receptors (designated EP subtypes 1-4) have gained much of attention. The advantage of targeting these receptors is that their modulation, unlike inhibition of COX-2, would not affect other prostanoids with beneficial physiological functions.

Results

LP S +

LP S

ro l Co nt

Bu ta Bu ta

LP S +

LP S

Co nt ro l

0

-

+ -

+

+ +

+ +

h

l

+ -

24

h

Microglia

600

Microglia

***

**

p38 MAPK, ERK1/2 and JNK contribute to the anti-inflammatory effects mediated by EP2

150 100

200

50

) )

C)

+ ta u B

P

C) (I: y ol

PGE2 (pg/ml)

0

0

Bu ta

+

Po

I: ly(

)

ta Bu

Po ly (I: C

Co nt ro l

20

100

Control

0

Control

Poly(I:C)

l

Control

Poly(I:C)

Poly(I:C)

***

200

p-ERK (44/42 kDa)

150

pp38-MAPK (43 kDa) p38-MAPK (43 kDa) 150

l

50

)

LPS (10ng/ml) Poly(I:C) (25µg/ml Butaprost

-

+ -

+ -

-

+ - + + +

-

+ -

+ -

-

+ - + + +

Bu ta

+

Po ly (I: C

Po ly (I: C)

co nt ro l

0

LPS (10ng/ml) Poly(I:C) (25µg/ml Butaprost

150

150

*** 100

50

0

*** 100

50

0 Control

PPJNK/ -actin (% of PolyI:C)

150

Poly(I:C)

Control

Poly(I:C)

CCL2 Relative expression (% Poly(I:C) control)

ERK (44/42 kDa)

TNF Relative expression (% of Poly(I:C) control)

100

IL-6 Relative expression (% of Poly(I:C) control)

CCL2/GAPDH Fold induction (Relative to control)

Po ly (I: C)

Co nt ro l

Microglia

100

200

0

l tro n Co Bu ta

0

40

150

**

50

0

20

Po ly Bu (I: C) ta + Po ly (I: C)

50

300

**

***

200

40

0

60

250

(I: C

100

60

100

Po ly

TNF pg/ml

200

50

**

TNF- pg/ml

80

300

***

100

MG MG-Depleted

+

*

Bu ta

150

IL-6 pg/ml

p.ERK/ERK (% of PolyI:C)

*

100

400

IL-6 pg/ml

150

+ Bu ta

OHSCs

OHSCs

Clodronate

Po ly (I: C

Po ly (I: C)

Bu ta

Co nt ro l

) Po ly (I: C

Bu ta

Control

+

Po ly (I: C)

0 Bu ta

Co nt ro l

0

Microglial depletion reduces Poly(I:C)induced inflammatory markers in OHSCs

Bu ta

Merge

Po ly (I: C)

NeuN

TNFa pg/ml

GFAP

IL-6 pg/ml

400

Bu ta

200

Co nt ro l

Clodronate liposomes treatment does not deplete neurons or astrocytes

EP2 signaling suppresses proinflammatory cytokine and chemokine expression stimulated by TLR3 agonist

pp38/p38 (% of PolyI:C)

12

h

0 6

h

h 24

12

h 6

h 3

h 1

h 0

50

COX-2 (70 kDa)

LPS Poly(I:C) Butaprost

h

l

0

l

1

h

5

***

*** 100

+

LP S

)

Bu ta

+

Po l

y( I:C )

Bu ta

0

Microglia

Actin (42 kDa)

3

***

COX-2/ -actin (%of Poly(I:C)/LPS controls)

50

150

2

h

10

1

***

S

Bu ta

***

*

0

*** 100

50

0 Control

Poly(I:C)

** 100

50

Bu ta

+

Po ly

(I: C

)

Po ly (I: C)

Co nt ro l

0 Bu ta

TLR3/GAPDH Relative expression

***

3 TLR4/GAPDH Relative expression

MG MG-Depleted

15

+

LP

(I: ly Po

+ Bu ta

*** 100

Po ly (I: C

PGE2 (% of Poly(I:C)/LPS controls)

Clodronate

Microglia

150

0

LP

S

C)

C) (I: ly

Po

Co nt

ro l

Bu ta

0

50

LP S

Control

200

Bu ta

PGE2 (pg/ml)

400

**

100

Bu ta

Merge

NeuN

OHSCs

Po ly (I: C) +P ol y( I:C )

**

150

Bu ta

600

COX-2/GAPDH (% of Poly(I:C)/LPS controls)

OHSCs

Iba1

Butraprost affects microglial Iba1 immunoreactivity and morphology in Poly(I:C) challenged OHSCs, without affecting the overall number of microglial cells

Activation of EP2 reduces PGE2 release in microglia by modulating COX-2

Bu ta Po l y( Bu I:C ta ) + Po ly (I: C)

TLR3 and TLR4 receptor expression elevated in challenged OHSCs is microglia dependent

Conclusion

Acknowledgements

p-JNK (54/46 kDa)

β-Actin (42 kDa)

Our data identify an anti-inflammatory function for EP2 signaling in diverse innate immune

LPS (10ng/ml) Poly(I:C) (25µg/ml Butaprost

-

+ -

+ -

-

+ +

+ +

Nizar M. Yousif is supported by a doctoral

responses, through a mechanism that involves the mitogen-activated protein kinases pathway. l Therefore, we suggest that targeting EP2 receptor pathway may serve as a therapeutic target for

scholarship from Landesgraduiertenförderung l

neurodegenerative pathologies driven by neuroinflammation.

Freiburg.

(LGFG-IGA), Albert-Ludwigs-Universität

[email protected]